FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510132475> ?p ?o ?g. }

• W2510132475 endingPage "2014" @default.
• W2510132475 startingPage "2004" @default.
• W2510132475 abstract "Summary Background Whole brain radiotherapy (WBRT) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC), although there have been no randomised clinical trials showing that WBRT improves either quality of life or overall survival. Even after treatment with WBRT, the prognosis of this patient group is poor. We aimed to establish whether WBRT could be omitted without a significant effect on survival or quality of life. Methods The Quality of Life after Treatment for Brain Metastases (QUARTZ) study is a non-inferiority, phase 3 randomised trial done at 69 UK and three Australian centres. NSCLC patients with brain metastases unsuitable for surgical resection or stereotactic radiotherapy were randomly assigned (1:1) to optimal supportive care (OSC) including dexamethasone plus WBRT (20 Gy in five daily fractions) or OSC alone (including dexamethasone). The dose of dexamethasone was determined by the patients' symptoms and titrated downwards if symptoms improved. Allocation to treatment group was done by a phone call from the hospital to the Medical Research Council Clinical Trials Unit at University College London using a minimisation programme with a random element and stratification by centre, Karnofsky Performance Status (KPS), gender, status of brain metastases, and the status of primary lung cancer. The primary outcome measure was quality-adjusted life-years (QALYs). QALYs were generated from overall survival and patients' weekly completion of the EQ-5D questionnaire. Treatment with OSC alone was considered non-inferior if it was no more than 7 QALY days worse than treatment with WBRT plus OSC, which required 534 patients (80% power, 5% [one-sided] significance level). Analysis was done by intention to treat for all randomly assigned patients. The trial is registered with ISRCTN, number ISRCTN3826061. Findings Between March 2, 2007, and Aug 29, 2014, 538 patients were recruited from 69 UK and three Australian centres, and were randomly assigned to receive either OSC plus WBRT (269) or OSC alone (269). Baseline characteristics were balanced between groups, and the median age of participants was 66 years (range 38–85). Significantly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported while patients were receiving WBRT, although there was no evidence of a difference in the rate of serious adverse events between the two groups. There was no evidence of a difference in overall survival (hazard ratio 1·06, 95% CI 0·90–1·26), overall quality of life, or dexamethasone use between the two groups. The difference between the mean QALYs was 4·7 days (46·4 QALY days for the OSC plus WBRT group vs 41·7 QALY days for the OSC group), with two-sided 90% CI of −12·7 to 3·3. Interpretation Although the primary outcome measure result includes the prespecified non-inferiority margin, the combination of the small difference in QALYs and the absence of a difference in survival and quality of life between the two groups suggests that WBRT provides little additional clinically significant benefit for this patient group. Funding Cancer Research UK, Medical Research Council Clinical Trials Unit at University College London, and the National Health and Medical Research Council in Australia." @default.
• W2510132475 created "2016-09-16" @default.
• W2510132475 creator A5002415902 @default.
• W2510132475 creator A5007868555 @default.
• W2510132475 creator A5008277154 @default.
• W2510132475 creator A5011703751 @default.
• W2510132475 creator A5011994090 @default.
• W2510132475 creator A5014097745 @default.
• W2510132475 creator A5021854143 @default.
• W2510132475 creator A5034779520 @default.
• W2510132475 creator A5038043021 @default.
• W2510132475 creator A5045005721 @default.
• W2510132475 creator A5049428169 @default.
• W2510132475 creator A5054720614 @default.
• W2510132475 creator A5057894542 @default.
• W2510132475 creator A5078663484 @default.
• W2510132475 creator A5081504508 @default.
• W2510132475 creator A5083082200 @default.
• W2510132475 creator A5086203007 @default.
• W2510132475 creator A5087314123 @default.
• W2510132475 creator A5089791856 @default.
• W2510132475 date "2016-10-01" @default.
• W2510132475 modified "2023-10-15" @default.
• W2510132475 title "Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial" @default.
• W2510132475 cites W1757407923 @default.
• W2510132475 cites W1963767762 @default.
• W2510132475 cites W1964621276 @default.
• W2510132475 cites W1980882294 @default.
• W2510132475 cites W1986777540 @default.
• W2510132475 cites W1990936385 @default.
• W2510132475 cites W1991003382 @default.
• W2510132475 cites W2004451956 @default.
• W2510132475 cites W2006324314 @default.
• W2510132475 cites W2009076763 @default.
• W2510132475 cites W2025833809 @default.
• W2510132475 cites W2028835275 @default.
• W2510132475 cites W2033980138 @default.
• W2510132475 cites W2035712312 @default.
• W2510132475 cites W2047930883 @default.
• W2510132475 cites W2048698607 @default.
• W2510132475 cites W2053800475 @default.
• W2510132475 cites W2057691996 @default.
• W2510132475 cites W2065321434 @default.
• W2510132475 cites W2071990624 @default.
• W2510132475 cites W2072044537 @default.
• W2510132475 cites W2074155910 @default.
• W2510132475 cites W2083854495 @default.
• W2510132475 cites W2102113843 @default.
• W2510132475 cites W2107529266 @default.
• W2510132475 cites W2109986616 @default.
• W2510132475 cites W2113465576 @default.
• W2510132475 cites W2113517821 @default.
• W2510132475 cites W2123101598 @default.
• W2510132475 cites W2127199535 @default.
• W2510132475 cites W2139027674 @default.
• W2510132475 cites W2152940159 @default.
• W2510132475 cites W2155073814 @default.
• W2510132475 cites W2158757066 @default.
• W2510132475 cites W2158789700 @default.
• W2510132475 cites W2168161641 @default.
• W2510132475 cites W2212917847 @default.
• W2510132475 cites W2228803286 @default.
• W2510132475 cites W2429254977 @default.
• W2510132475 cites W2473786944 @default.
• W2510132475 doi "https://doi.org/10.1016/s0140-6736(16)30825-x" @default.
• W2510132475 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5082599" @default.
• W2510132475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27604504" @default.
• W2510132475 hasPublicationYear "2016" @default.
• W2510132475 type Work @default.
• W2510132475 sameAs 2510132475 @default.
• W2510132475 citedByCount "494" @default.
• W2510132475 countsByYear W25101324752016 @default.
• W2510132475 countsByYear W25101324752017 @default.
• W2510132475 countsByYear W25101324752018 @default.
• W2510132475 countsByYear W25101324752019 @default.
• W2510132475 countsByYear W25101324752020 @default.
• W2510132475 countsByYear W25101324752021 @default.
• W2510132475 countsByYear W25101324752022 @default.
• W2510132475 countsByYear W25101324752023 @default.
• W2510132475 crossrefType "journal-article" @default.
• W2510132475 hasAuthorship W2510132475A5002415902 @default.
• W2510132475 hasAuthorship W2510132475A5007868555 @default.
• W2510132475 hasAuthorship W2510132475A5008277154 @default.
• W2510132475 hasAuthorship W2510132475A5011703751 @default.
• W2510132475 hasAuthorship W2510132475A5011994090 @default.
• W2510132475 hasAuthorship W2510132475A5014097745 @default.
• W2510132475 hasAuthorship W2510132475A5021854143 @default.
• W2510132475 hasAuthorship W2510132475A5034779520 @default.
• W2510132475 hasAuthorship W2510132475A5038043021 @default.
• W2510132475 hasAuthorship W2510132475A5045005721 @default.
• W2510132475 hasAuthorship W2510132475A5049428169 @default.
• W2510132475 hasAuthorship W2510132475A5054720614 @default.
• W2510132475 hasAuthorship W2510132475A5057894542 @default.
• W2510132475 hasAuthorship W2510132475A5078663484 @default.
• W2510132475 hasAuthorship W2510132475A5081504508 @default.
• W2510132475 hasAuthorship W2510132475A5083082200 @default.
• W2510132475 hasAuthorship W2510132475A5086203007 @default.
• W2510132475 hasAuthorship W2510132475A5087314123 @default.

• next